Sponsor

Alpha Biopharma (Jiangsu) Co., Ltd.

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Alpha Biopharma (Jiangsu) Co., Ltd. appears in 5 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials5
Recruiting shown2
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

5 shown
Zorifertinib With Osimertinib for NSCLC With Meningeal ProgressionNCT07361705 · lead sponsor · 2026-01-31
RECRUITING
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) MetastasesNCT07143045 · lead sponsor · 2025-12-29
RECRUITING
Material Balance of [14C]Zorifertinib in Healthy Adult Male Participants in ChinaNCT07620951 · lead sponsor · 2026-07-06
COMPLETED
First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) MetastasesNCT03653546 · lead sponsor · 2018-10-29
COMPLETED
Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKINCT07551414 · collaborator · 2026-05-30
NOT_YET_RECRUITING

Sponsor roles

lead sponsor4
collaborator1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.